{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-23-000004","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2023-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.604433+00:00","generated_at":"2026-06-17T05:51:28.945653+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aurinia reports positive renal biopsy data for LUPKYNIS in lupus nephritis","bullets":["Repeat biopsies from 16 voclosporin and 10 control patients over 18 months.","Activity scores improved similarly in both arms; chronicity scores stable.","Data differentiates LUPKYNIS from first-generation CNIs on nephrotoxicity.","Further data to be presented at Congress of Clinical Rheumatology May 4-7, 2023.","Conference call/webcast at 8:30 am EDT on April 5, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-23-000004","json":"https://secwatch.observer/filing/0001600620-23-000004.json","markdown":"https://secwatch.observer/filing/0001600620-23-000004.md","text":"https://secwatch.observer/filing/0001600620-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000004/0001600620-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000004/auph-20230405.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:51:28.945653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}